{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:01:52Z","timestamp":1787508112172,"version":"build-2736575974"},"publisher-location":"New York, NY","reference-count":32,"publisher":"Springer US","isbn-type":[{"value":"9781071631744","type":"print"},{"value":"9781071631751","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_35","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:02:13Z","timestamp":1684465333000},"page":"533-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay"],"prefix":"10.1007","author":[{"given":"Gary W.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Llusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus B.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"35_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","volume":"66","author":"XL Zheng","year":"2015","unstructured":"Zheng XL (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211\u2013225","journal-title":"Annu Rev Med"},{"key":"35_CR2","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","volume":"100","author":"JF Dong","year":"2002","unstructured":"Dong JF, Moake JL, Nolasco L et al (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033\u20134039","journal-title":"Blood"},{"key":"35_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/ATVBAHA.113.302547","volume":"34","author":"J Bao","year":"2014","unstructured":"Bao J, Xiao J, Mao Y, Zheng XL (2014) Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. Arterioscler Thromb Vasc Biol 34:397\u2013407","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"35_CR4","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1055\/s-0038-1660505","volume":"2","author":"LN van der Vorm","year":"2018","unstructured":"van der Vorm LN, Remijn JA, de Laat B, Huskens D (2018) Effects of plasmin on von Willebrand factor and platelets: a narrative review. TH Open 2:e218\u2013e228","journal-title":"TH Open"},{"key":"35_CR5","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846","journal-title":"Blood"},{"key":"35_CR6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578\u20131584","journal-title":"N Engl J Med"},{"key":"35_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.13654","volume":"171","author":"S Hassan","year":"2015","unstructured":"Hassan S, Westwood JP, Ellis D, Laing C, Mc Guckin S, Benjamin S, Scully M (2015) The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP registry. Br J Haematol 171:830\u2013835","journal-title":"Br J Haematol"},{"key":"35_CR8","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486\u20132495","journal-title":"J Thromb Haemost"},{"key":"35_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.5858\/arpa.2013-0170-OA","volume":"138","author":"BD Barrows","year":"2014","unstructured":"Barrows BD, Teruya J (2014) Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch Pathol Lab Med 138:546\u2013549","journal-title":"Arch Pathol Lab Med"},{"key":"35_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/trf.13359","volume":"56","author":"NT Connell","year":"2016","unstructured":"Connell NT, Cheves T, Sweeney JD (2016) Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion 56:354\u2013359","journal-title":"Transfusion"},{"key":"35_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/bjh.15219","volume":"184","author":"W Thomas","year":"2019","unstructured":"Thomas W, Cutler JA, Moore GW, McDonald V, Hunt BJ (2019) The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura. Br J Haematol 184:1026\u20131032","journal-title":"Br J Haematol"},{"key":"35_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/rth2.12461","volume":"5","author":"N Beranger","year":"2020","unstructured":"Beranger N, Benghezal S, Joly BS et al (2020) Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Res Pract Thromb Haemost 5:81\u201393","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"35_CR13","first-page":"278","volume":"5","author":"S Geiter","year":"2021","unstructured":"Geiter S, Wagner L, Binder NB, Budde U (2021) Evaluation of a new fully automated ADAMTS13 activity assay. Res Pract Thromb Haemost 5(Suppl 2):278. Abstract PB0353","journal-title":"Res Pract Thromb Haemost"},{"key":"35_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jth.15157","volume":"19","author":"EJ Favaloro","year":"2021","unstructured":"Favaloro EJ, Mohammed S, Chapman K et al (2021) A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost 19:417\u2013428","journal-title":"J Thromb Haemost"},{"key":"35_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2496\u20132502","journal-title":"J Thromb Haemost"},{"key":"35_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ijlh.12718","volume":"40","author":"K Langley","year":"2018","unstructured":"Langley K, Fretwell R, Kitchen S et al (2018) Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays. Int J Lab Hematol 40:21\u201325","journal-title":"Int J Lab Hematol"},{"key":"35_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ajh.26241","volume":"96","author":"EJ Favaloro","year":"2021","unstructured":"Favaloro EJ, Pasalic L, Henry B, Lippi G (2021) Laboratory testing for ADAMTS13: utility for TTP diagnosis\/exclusion and beyond. Am J Hematol 96:1049\u20131055","journal-title":"Am J Hematol"},{"key":"35_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2021.02.012","volume":"201","author":"PL Turecek","year":"2021","unstructured":"Turecek PL, Peck RC, Rangarajan S et al (2021) Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res 201:100\u2013112","journal-title":"Thromb Res"},{"key":"35_CR19","volume-title":"Fundamentals of biomedical science: haematology","author":"GW Moore","year":"2021","unstructured":"Moore GW (2021) Acquired disorders of hemostasis. In: Moore GW, Knight G, Blann AD (eds) Fundamentals of biomedical science: haematology, 3rd edn. Oxford University Press, Oxford","edition":"3"},{"key":"35_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0041-1727282","volume":"47","author":"EJ Favaloro","year":"2021","unstructured":"Favaloro EJ, Henry BM, Lippi G (2021) Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 47:400\u2013418","journal-title":"Semin Thromb Hemost"},{"key":"35_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fneur.2019.00772","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen X, Cheng X, Zhang S, Wu D (2019) ADAMTS13: an emerging target in stroke therapy. Front Neurol 10:772","journal-title":"Front Neurol"},{"key":"35_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/ijlh.13295","volume":"42","author":"I Mackie","year":"2020","unstructured":"Mackie I, Mancini I, Muia J, Kremer Hovinga J, Nair S, Machin S, Baker R (2020) International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol 42:685\u2013696","journal-title":"Int J Lab Hematol"},{"key":"35_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1182\/bloodadvances.2019000979","volume":"4","author":"A Taylor","year":"2020","unstructured":"Taylor A, Vendramin C, Singh D, Brown MM, Scully M (2020) von Willebrand factor\/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome. Blood Adv 4:398\u2013407","journal-title":"Blood Adv"},{"key":"35_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jth.12881","volume":"13","author":"AR Hubbard","year":"2015","unstructured":"Hubbard AR, Heath AB, Kremer Hovinga JA, Subcommittee on von Willebrand Factor (2015) Establishment of the WHO 1st international standard ADAMTS13, plasma (12\/252): communication from the SSC of the ISTH. J Thromb Haemost 13:1151\u20131153","journal-title":"J Thromb Haemost"},{"key":"35_CR25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00296-021-04865-9","volume":"41","author":"JE Gehin","year":"2021","unstructured":"Gehin JE, Klaasen RA, Norli ES et al (2021) Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort. Rheumatol Int 41:1657\u20131665","journal-title":"Rheumatol Int"},{"key":"35_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1177\/0300060517695646","volume":"45","author":"H Chen","year":"2017","unstructured":"Chen H, Fu A, Wang J et al (2017) Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res 45:1253\u20131260","journal-title":"J Int Med Res"},{"key":"35_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346","journal-title":"N Engl J Med"},{"key":"35_CR28","doi-asserted-by":"publisher","unstructured":"Moore GW, Vetr H, Binder NB (this volume) ADAMTS13 antibody and inhibitor assays. In: Favaloro EJ, Gosselin RC (eds) Haemostasis and thrombosis: methods and protocols, 2nd edn. Springer, New York, pp 549\u2013565. https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_36","DOI":"10.1007\/978-1-0716-3175-1_36"},{"key":"35_CR29","doi-asserted-by":"publisher","unstructured":"Favaloro EJ, Chapman K, Mohammed S, Vong R, Pasalic L (2023) Identification of ADAMTS13 inhibitors in acquired TTP. In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols. Methods in molecular biology. Springer, New York, pp 505\u2013521. https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_33","DOI":"10.1007\/978-1-0716-3175-1_33"},{"key":"35_CR30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","volume":"5","author":"SC Meyer","year":"2007","unstructured":"Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA (2007) Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 5:866\u2013867","journal-title":"J Thromb Haemost"},{"key":"35_CR31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2004-06-2096","volume":"105","author":"JD Studt","year":"2005","unstructured":"Studt JD, Kremer Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, L\u00e4mmle B (2005) Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105:542\u2013544","journal-title":"Blood"},{"key":"35_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1160\/TH08-10-0677","volume":"101","author":"Z Zhou","year":"2009","unstructured":"Zhou Z, Han H, Cruz MA, L\u00f3pez J, Dong JF, Guchhait P (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101:1070\u20131077","journal-title":"Thromb Haemost"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:06:53Z","timestamp":1684465613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":32,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_35","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}